Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Moores

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Neurosurgical Focus|June 24, 2010
Cranioplasty complications following wartime decompressive craniectomyFrederick L Stephens, Correy M Mossop, Randy S Bell, et al.
Biochemical Pharmacology|February 5, 2000
Selective binding of the truncated form of the chemokine CKbeta8 (25-99) to CC chemokine receptor 1(CCR1)T A Berkhout, J Gohil, P Gonzalez, et al.
The Biochemical Journal|October 15, 1990
SK&F 96365, a novel inhibitor of receptor-mediated calcium entryJ E Merritt, W P Armstrong, C D Benham, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 1998
Identification of a truncated form of the CC chemokine CK beta-8 demonstrating greatly enhanced biological activityC H Macphee, E R Appelbaum, K Johanson, et al.
The Biochemical Journal|February 20, 1999
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitorC H MacPhee, K E Moores, H F Boyd, et al.
Journal of Geophysical Research. Planets|June 12, 2020
The Vertical Dust Profile over Gale Crater, MarsScott D Guzewich, C E Newman, M D Smith, et al.
Journal of Medicinal Chemistry|September 5, 2003
CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approachTheo A Berkhout, Frank E Blaney, Angela M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2000
N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2H F Boyd, S C Fell, S T Flynn, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2003
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2Josie A Blackie, Jackie C Bloomer, Murray J B Brown, et al.
Life Sciences in Space Research|April 26, 2024
The COSPAR planetary protection policy for missions to Icy Worlds: A review of history, current scientific knowledge, and future directionsP T Doran, A Hayes, O Grasset, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Neurosurgical Focus|June 24, 2010
Cranioplasty complications following wartime decompressive craniectomyFrederick L Stephens, Correy M Mossop, Randy S Bell, et al.
Biochemical Pharmacology|February 5, 2000
Selective binding of the truncated form of the chemokine CKbeta8 (25-99) to CC chemokine receptor 1(CCR1)T A Berkhout, J Gohil, P Gonzalez, et al.
The Biochemical Journal|October 15, 1990
SK&F 96365, a novel inhibitor of receptor-mediated calcium entryJ E Merritt, W P Armstrong, C D Benham, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 1998
Identification of a truncated form of the CC chemokine CK beta-8 demonstrating greatly enhanced biological activityC H Macphee, E R Appelbaum, K Johanson, et al.
The Biochemical Journal|February 20, 1999
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitorC H MacPhee, K E Moores, H F Boyd, et al.
Journal of Geophysical Research. Planets|June 12, 2020
The Vertical Dust Profile over Gale Crater, MarsScott D Guzewich, C E Newman, M D Smith, et al.
Journal of Medicinal Chemistry|September 5, 2003
CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approachTheo A Berkhout, Frank E Blaney, Angela M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters|November 22, 2000
N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2H F Boyd, S C Fell, S T Flynn, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2003
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2Josie A Blackie, Jackie C Bloomer, Murray J B Brown, et al.
Life Sciences in Space Research|April 26, 2024
The COSPAR planetary protection policy for missions to Icy Worlds: A review of history, current scientific knowledge, and future directionsP T Doran, A Hayes, O Grasset, et al.
Pageof 5